Literature DB >> 20145632

Allosteric antipsychotics: m4 muscarinic potentiators as novel treatments for schizophrenia.

Martilias Farrell1, Bryan L Roth.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20145632      PMCID： PMC3055359          DOI： 10.1038/npp.2009.206

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN： 0893-133X            Impact factor:   7.853


× No keyword cloud information.
  11 in total

1.  Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice.

Authors:  J Gomeza; L Zhang; E Kostenis; C Felder; F Bymaster; J Brodkin; H Shannon; B Xia; C Deng; J Wess
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

Review 2.  Allosteric binding sites on cell-surface receptors: novel targets for drug discovery.

Authors:  Arthur Christopoulos
Journal:  Nat Rev Drug Discov       Date:  2002-03       Impact factor: 84.694

Review 3.  Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia.

Authors:  Bryan L Roth; Douglas J Sheffler; Wesley K Kroeze
Journal:  Nat Rev Drug Discov       Date:  2004-04       Impact factor: 84.694

4.  The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions?

Authors:  Marilyn A Davies; Beth Ann Compton-Toth; Sandra J Hufeisen; Herbert Y Meltzer; Bryan L Roth
Journal:  Psychopharmacology (Berl)       Date:  2004-10-13       Impact factor: 4.530

5.  The effects of diisopropylfluorophosphonate in schizophrenia and manic depressive psychosis.

Authors:  D W ROWNTREE; S NEVIN; A WILSON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1950-02       Impact factor: 10.154

6.  Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice.

Authors:  D J Gerber; T D Sotnikova; R R Gainetdinov; S Y Huang; M G Caron; S Tonegawa
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

7.  Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.

Authors:  N C Bodick; W W Offen; A I Levey; N R Cutler; S G Gauthier; A Satlin; H E Shannon; G D Tollefson; K Rasmussen; F P Bymaster; D J Hurley; W Z Potter; S M Paul
Journal:  Arch Neurol       Date:  1997-04

Review 8.  Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects.

Authors:  S Snyder; D Greenberg; H I Yamamura
Journal:  Arch Gen Psychiatry       Date:  1974-07

9.  Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice.

Authors:  H E Shannon; K Rasmussen; F P Bymaster; J C Hart; S C Peters; M D Swedberg; L Jeppesen; M J Sheardown; P Sauerberg; A Fink-Jensen
Journal:  Schizophr Res       Date:  2000-05-05       Impact factor: 4.939

10.  Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia.

Authors:  W Y Chan; D L McKinzie; S Bose; S N Mitchell; J M Witkin; R C Thompson; A Christopoulos; S Lazareno; N J M Birdsall; F P Bymaster; C C Felder
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-04       Impact factor: 11.205
View more
  11 in total

Review 1.  Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors.

Authors:  Craig W Lindsley; Kyle A Emmitte; Corey R Hopkins; Thomas M Bridges; Karen J Gregory; Colleen M Niswender; P Jeffrey Conn
Journal:  Chem Rev       Date:  2016-02-16       Impact factor: 60.622

2.  Optimization of M4 positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacology.

Authors:  Bruce J Melancon; Michael R Wood; Meredith J Noetzel; Kellie D Nance; Eileen M Engelberg; Changho Han; Atin Lamsal; Sichen Chang; Hyekyung P Cho; Frank W Byers; Michael Bubser; Carrie K Jones; Colleen M Niswender; Michael W Wood; Darren W Engers; Dedong Wu; Nicholas J Brandon; Mark E Duggan; P Jeffrey Conn; Thomas M Bridges; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2017-04-13       Impact factor: 2.823

Review 3.  Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits.

Authors:  Briana J Davie; Arthur Christopoulos; Peter J Scammells
Journal:  ACS Chem Neurosci       Date:  2013-05-23       Impact factor: 4.418

4.  Muscarinic Acetylcholine Receptor Subtypes as Potential Drug Targets for the Treatment of Schizophrenia, Drug Abuse and Parkinson's Disease.

Authors:  Ditte Dencker; Morgane Thomsen; Gitta Wörtwein; Pia Weikop; Yinghong Cui; Jongrye Jeon; Jürgen Wess; Anders Fink-Jensen
Journal:  ACS Chem Neurosci       Date:  2012       Impact factor: 4.418

5.  Discovery and SAR of a novel series of potent, CNS penetrant M4 PAMs based on a non-enolizable ketone core: Challenges in disposition.

Authors:  Michael R Wood; Meredith J Noetzel; James C Tarr; Alice L Rodriguez; Atin Lamsal; Sichen Chang; Jarrett J Foster; Emery Smith; Peter Chase; Peter S Hodder; Darren W Engers; Colleen M Niswender; Nicholas J Brandon; Michael W Wood; Mark E Duggan; P Jeffrey Conn; Thomas M Bridges; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2016-07-21       Impact factor: 2.823

6.  Discovery of a novel 2,4-dimethylquinoline-6-carboxamide M4 positive allosteric modulator (PAM) chemotype via scaffold hopping.

Authors:  Madeline F Long; Julie L Engers; Sichen Chang; Xiaoyan Zhan; Rebecca L Weiner; Vincent B Luscombe; Alice L Rodriguez; Hyekyung P Cho; Colleen M Niswender; Thomas M Bridges; P Jeffrey Conn; Darren W Engers; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2017-10-09       Impact factor: 2.823

7.  Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amides.

Authors:  James C Tarr; Michael R Wood; Meredith J Noetzel; Jeanette L Bertron; Rebecca L Weiner; Alice L Rodriguez; Atin Lamsal; Frank W Byers; Sichen Chang; Hyekyung P Cho; Carrie K Jones; Colleen M Niswender; Michael W Wood; Nicholas J Brandon; Mark E Duggan; P Jeffrey Conn; Thomas M Bridges; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2017-05-06       Impact factor: 2.823

8.  Challenges in the development of an M4 PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogs.

Authors:  Michael R Wood; Meredith J Noetzel; Michael S Poslusney; Bruce J Melancon; James C Tarr; Atin Lamsal; Sichen Chang; Vincent B Luscombe; Rebecca L Weiner; Hyekyung P Cho; Michael Bubser; Carrie K Jones; Colleen M Niswender; Michael W Wood; Darren W Engers; Nicholas J Brandon; Mark E Duggan; P Jeffrey Conn; Thomas M Bridges; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2016-11-30       Impact factor: 2.823

9.  Discovery of a novel, CNS penetrant M4 PAM chemotype based on a 6-fluoro-4-(piperidin-1-yl)quinoline-3-carbonitrile core.

Authors:  Blake R Bewley; Paul K Spearing; Rebecca L Weiner; Vincent B Luscombe; Xiaoyan Zhan; Sichen Chang; Hyekyung P Cho; Alice L Rodriguez; Colleen M Niswender; P Jeffrey Conn; Thomas M Bridges; Darren W Engers; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2017-08-20       Impact factor: 2.823

10.  Discovery and optimization of a novel series of highly CNS penetrant M4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3-d]pyrimidine core.

Authors:  Michael R Wood; Meredith J Noetzel; Julie L Engers; Katrina A Bollinger; Bruce J Melancon; James C Tarr; Changho Han; Mary West; Alison R Gregro; Atin Lamsal; Sichen Chang; Sonia Ajmera; Emery Smith; Peter Chase; Peter S Hodder; Michael Bubser; Carrie K Jones; Corey R Hopkins; Kyle A Emmitte; Colleen M Niswender; Michael W Wood; Mark E Duggan; P Jeffrey Conn; Thomas M Bridges; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2016-05-05       Impact factor: 2.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.